OBJECTIVES: Newborn bloodspot screening (NBS) panels have expanded to include conditions for which treatment effects are less certain, creating debate about population-based screening criteria. We investigated Canadian public expectations and values regarding the types of conditions that should be included in NBS and whether parents should provide consent. METHODS: Eight focus groups (FG; n = 60) included education, deliberative discussion and pre-/post-questionnaires. Data were analysed quantitatively and qualitatively. RESULTS: Quantitatively, the majority supported NBS for serious disorders for which treatment is not available (95-98, 82%). A majority endorsed screening without explicit consent (77-88%) for treatable disorders, but 62% supported unpressured choice for screening for untreatable disorders. Qualitatively, participants valued treatment-related benefits for infants and informational benefits for families. Concern for anxiety, stigma and unwanted knowledge depended upon disease context and strength of countervailing benefits. CONCLUSIONS: Anticipated benefits of expanded infant screening were prioritized over harms, with information provision perceived as a mechanism for mitigating harms and enabling choice. However, we urge caution around the potential for public enthusiasm to foster unlimited uptake of infant screening technologies.
OBJECTIVES: Newborn bloodspot screening (NBS) panels have expanded to include conditions for which treatment effects are less certain, creating debate about population-based screening criteria. We investigated Canadian public expectations and values regarding the types of conditions that should be included in NBS and whether parents should provide consent. METHODS: Eight focus groups (FG; n = 60) included education, deliberative discussion and pre-/post-questionnaires. Data were analysed quantitatively and qualitatively. RESULTS: Quantitatively, the majority supported NBS for serious disorders for which treatment is not available (95-98, 82%). A majority endorsed screening without explicit consent (77-88%) for treatable disorders, but 62% supported unpressured choice for screening for untreatable disorders. Qualitatively, participants valued treatment-related benefits for infants and informational benefits for families. Concern for anxiety, stigma and unwanted knowledge depended upon disease context and strength of countervailing benefits. CONCLUSIONS: Anticipated benefits of expanded infant screening were prioritized over harms, with information provision perceived as a mechanism for mitigating harms and enabling choice. However, we urge caution around the potential for public enthusiasm to foster unlimited uptake of infant screening technologies.
Authors: Jerry R Mendell; Chris Shilling; Nancy D Leslie; Kevin M Flanigan; Roula al-Dahhak; Julie Gastier-Foster; Kelley Kneile; Diane M Dunn; Brett Duval; Alexander Aoyagi; Cindy Hamil; Maha Mahmoud; Kandice Roush; Lauren Bird; Chelsea Rankin; Heather Lilly; Natalie Street; Ram Chandrasekar; Robert B Weiss Journal: Ann Neurol Date: 2012-03 Impact factor: 10.422
Authors: S G Nicholls; L Tessier; H Etchegary; J C Brehaut; B K Potter; R Z Hayeems; P Chakraborty; J Marcadier; J Milburn; D Pullman; L Turner; B J Wilson Journal: BMJ Open Date: 2014-11-24 Impact factor: 2.692
Authors: Sylvia M van der Pal; Sophie Wins; Jasmijn E Klapwijk; Tessa van Dijk; Adriana Kater-Kuipers; Catharina P B van der Ploeg; Suze M P J Jans; Stephan Kemp; Rendelien K Verschoof-Puite; Lion J M van den Bosch; Lidewij Henneman Journal: PLoS One Date: 2022-08-18 Impact factor: 3.752
Authors: Maartje Blom; Michiel H D Schoenaker; Myrthe Hulst; Martine C de Vries; Corry M R Weemaes; Michèl A A P Willemsen; Lidewij Henneman; Mirjam van der Burg Journal: Front Immunol Date: 2019-11-06 Impact factor: 7.561
Authors: Courtney K Wallingford; Katrina Cutler; Satrio Nindyo Istiko; Lindsay F Fowles; Rachel Lamb; Jessica Bean; Louise Healy; Gary Hondow; Gregory Pratt; Miranda E Vidgen; Nicola Waddell; Erin Evans; David Bunker; Aideen M McInerney-Leo Journal: Front Genet Date: 2020-10-15 Impact factor: 4.599